NCT05414123: A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

NCT05414123
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain, Leptomeningeal Disease 
Additional Notes: Patients must have clinically suspected leptomeningeal disease
Exclusions: 
https://ClinicalTrials.gov/show/NCT05414123

Comments are closed.

Up ↑